Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
申请人:Castro C. Alfredo
公开号:US20060025460A1
公开(公告)日:2006-02-02
One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
[EN] CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] CYCLOALKYLNITRILE PYRAZOLOPYRIDONES UTILISÉES COMME INHIBITEURS DE LA JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2014146490A1
公开(公告)日:2014-09-25
Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9
申请人:Boehringer Ingelheim International GmbH
公开号:US20180044335A1
公开(公告)日:2018-02-15
The present invention encompasses compounds of general formula (I) wherein the groups R
1
to R
9
, X
1
and X
2
have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer, pharmaceutical preparations containing such compounds and their uses as a medicament.
[EN] CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] PYRIDONES CYCLOALKYLE PYRAZOLO NITRILE EN TANT QU'INHIBITEURS DE JANUS KINASE
申请人:MERCK SHARP & DOHME
公开号:WO2014146246A1
公开(公告)日:2014-09-25
The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
[EN] PYRROLO[2,3-B]PYRIDINES AS HPK1 INHIBITOR AND USES THEREOF<br/>[FR] PYRROLO[2,3-B]PYRIDINES UTILISÉS EN TANT QU'INHIBITEUR DE HPK1 ET LEURS UTILISATIONS
申请人:BEIGENE LTD
公开号:WO2020103896A1
公开(公告)日:2020-05-28
Disclosed herein is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.